Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases. The CLYM news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Climb Bio communicates progress on its pipeline and corporate activities.
News about Climb Bio frequently highlights clinical development updates for its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. Company announcements have covered initiation and enrollment of Phase 2 and Phase 1b/2a trials of budoprutug in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, as well as a Phase 1 study of a subcutaneous formulation in healthy volunteers. Climb Bio also reports on preclinical and early clinical data, such as long-term follow-up results in pMN and nonhuman primate data for CLYM116 in IgA nephropathy.
Investors and followers can use this news feed to track regulatory milestones, including investigational new drug and clinical trial application clearances, initiation of Phase 1 studies for CLYM116, and updates on trial site activation and dosing progress. Corporate developments, such as leadership appointments, inducement equity grants under the company’s 2025 Inducement Plan, and participation in healthcare and biotechnology investor conferences, are also common topics in Climb Bio’s news flow.
By monitoring CLYM news on Stock Titan, readers gain a centralized view of Climb Bio’s disclosed clinical timelines, data presentations at scientific meetings, and strategic licensing arrangements related to its pipeline. This context can help users understand how the company’s immune-mediated disease programs are advancing through development.
Climb Bio (Nasdaq: CLYM) will host an R&D Spotlight webcast on May 5, 2026 at 8:00 a.m. ET focused on budoprutug, an anti-CD19 monoclonal antibody for B-cell mediated diseases. The event will cover target rationale, clinical study design, dose selection, and development strategy.
Speakers include Climb Bio management and David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge. A replay will be available on the company's investor website about two hours after the live webcast and archived for at least 30 days.
Climb Bio (Nasdaq: CLYM) announced FDA Fast Track Designation for budoprutug to treat primary membranous nephropathy (pMN).
Budoprutug showed complete peripheral B-cell depletion in 100% (5/5) of Phase 1b patients, serologic remission in 3/3 evaluable patients, and complete/partial clinical remission in 5/5 by week 48. A global Phase 2 study (PrisMN) is enrolling; initial data expected H2 2026.
Climb Bio (Nasdaq: CLYM) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. The company ended 2025 with $160.7 million in cash and expects runway into 2028. Multiple budoprutug trials are underway, a subcutaneous dosing study completed, and several initial data readouts are expected across 2026.
CLYM116 Phase 1 enrollment continues with initial healthy-volunteer data anticipated mid-2026; IND clearance obtained in China for a parallel SLE study.
Climb Bio (Nasdaq: CLYM) announced that its executive team will present at three investor conferences in Feb–Mar 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 12, Oppenheimer Healthcare Life Sciences on Feb 25, and Leerink Global Healthcare on Mar 9.
The presentations are fireside chats with live webcasts available via the company’s Investors & Media website; replays will be posted about two hours after each event and archived for at least 30 days.
Climb Bio (NASDAQ: CLYM) reported clinical and corporate progress and refreshed guidance on Jan 8, 2026. Key program updates include first patient dosed in the PrisMN Phase 2 trial for primary membranous nephropathy and ongoing dosing in budoprutug Phase 1b/2a ITP and Phase 1b SLE trials, plus IND clearance for a China SLE trial. First cohorts were dosed in a subcutaneous budoprutug Phase 1 healthy volunteer study. CLYM116 advanced into a Phase 1 healthy volunteer study after an in-license and FPI; partner Mabworks cleared a China IND. The company reported 20 regulatory clearances, activation of 45 trial sites, and cash runway expected into 2028. Multiple initial data readouts are anticipated across budoprutug and CLYM116 in 2026.
Climb Bio (Nasdaq: CLYM) granted an inducement equity award under its 2025 Inducement Plan to one new employee on November 24, 2025 pursuant to Nasdaq Listing Rule 5635(c)(4).
The award is a non-statutory stock option for 120,000 shares at an exercise price of $1.76 per share (equal to the Nasdaq closing price on November 24, 2025), with a 10-year term and four-year vesting: 25% after one year and the remainder in 36 equal monthly installments, subject to continued service and the terms of the award agreement and the 2025 Inducement Plan, as amended.
Climb Bio (NASDAQ: CLYM) reported Q3 2025 results and clinical progress on Nov 6, 2025. The company held $175.8 million in cash, cash equivalents and marketable securities as of Sept 30, 2025, which management expects will fund operations through 2027. Key clinical programs advanced: the PrisMN Phase 2 trial in primary membranous nephropathy has been initiated; a subcutaneous Phase 1 for budoprutug is enrolling with initial data expected H1 2026; ITP and SLE Phase 1b/2a trials expect initial data H2 2026. CLYM116 received regulatory clearance for Phase 1 dosing, with first subject anticipated by year-end 2025 and initial data mid-2026. Q3 operating items: R&D $9.1M, G&A $5.8M, other income $2.0M.
Leadership strengthened with appointments including Susan Altschuller, Ph.D., MBA as CFO.
Climb Bio (Nasdaq: CLYM) announced that executives will participate in three investor conferences in November–December 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 11:30 a.m. ET, Baird Biotech Discovery Series (virtual) on Nov 18, 2025 at 1:30 p.m. ET, and Piper Sandler’s 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 9:30 a.m. ET.
Each appearance will include fireside chats; select events include one-on-one investor meetings. Live webcasts and replay recordings will be available via the Investors & Media section of the Climb Bio website and will be archived for at least 30 days.
Climb Bio (Nasdaq: CLYM) announced two senior hires on Oct 21, 2025: Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy. The appointments aim to support execution of clinical development for budoprutug and CLYM116 and to improve operational and workforce capabilities.
Climb Bio granted inducement equity awards on Oct 20, 2025: non-statutory stock options to acquire an aggregate of 360,000 shares, exercise price $2.32 (Nasdaq close on Oct 20, 2025), ten-year term, vesting over four years (25% after one year, then monthly over 36 months).
Climb Bio (Nasdaq: CLYM) will present preclinical and clinical data at ASN Kidney Week 2025 in Houston, Nov 6-9, 2025.
CLYM116: preclinical data show the Fc-engineered anti-APRIL mAb promoted APRIL degradation, enhanced antibody recycling and produced deep, durable IgA reduction in models, supporting development for IgA nephropathy (IgAN). Presentation: Poster SA-PO0253 on Nov 8, 2025, 10:00 AM–12:00 PM.
Budoprutug: published Phase 1b long-term follow-up (NCT04652570) in primary membranous nephropathy reported proteinuria control up to 3 years after up to four doses in four patients; three required no further immunosuppression and no clinically significant treatment-related adverse events were observed. Abstracts available on the ASN Kidney Week website.